Fulranumab adjunctive therapy for osteoarthritis of the hip or knee

Phase 3, randomised, double-blind trial in hip osteoarthritis and knee osteoarthritis (OA) comparing Fulranumab adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoints: Change from baseline to Week 16 in WOMAC pain subscale and Change from baseline to Week 16 in WOMAC physical function subscale. Started May 2015; status: completed.